Stock’s Trend Analysis Report – MannKind Corporation (NASDAQ:MNKD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).
Houston, TX –March 22, 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s focus is on: MNKD, ARIA
The worthwhile stocks of the Biotechnology industry of the Healthcare Sector are in today’s spotlight, which scored heavy volume. The active stocks were MannKind Corporation (NASDAQ:MNKD) which showed higher volume in its industry and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), which gained traders attention mainly due to superb trade.
MannKind Corporation (NASDAQ:MNKD) unveiled its financial results for the 4th Q and fiscal year 2012. The operating expenses of the company remained $33.5 million for the 4th Q of 2012, $2.9 million up, in comparison to the similar Q of 2011 of $30.6 million.
How Should Investors Trade MNKD Now? Don’t Trade MNKD Until You Read This TREND ANALYSIS REPORT
The operating expenses of MannKind Corporation reported $147.0 million for the FY 2012, $6.4 million up, versus the year ago was $140.6 million.
MannKind Corporation showing bullish momentum during previous trade. MannKind Corporation (NASDAQ:MNKD) started its trading session with the price of $3.41 and closed at the price of $3.37 by scoring +0.60%. The 52 week range of MNKD was $1.57 – $3.67.
MNKD’s stocks traded with total volume of 3.40 million shares, while the average trading capacity remained 4.80 million shares. Previous 5 days graph demonstrated a positive move of 10.13%. MNKD’s quarterly performance remained in the green with the percentage of 54.59, while its year to date performance showed that the stock climbed overall 45.89%.
How Should Investors React To MNKD Now? Find Out In This TREND ANALYSIS REPORT
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported that, in Washington, it has plans for preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, it will be happening, Saturday, April 6, 2013, to Wednesday, April 10, 2013.
Get A Free Report And Detailed Analysis On ARIA CLICK HERE To Read
During the previous trade, Biotechnology company showing negative moves, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded with a decline of -3.62% and closed at $19.71 after gaining total volume of 3.18 million shares. Its opening price was $20.41. Ariad Pharmaceuticals’ EPS is $-1.36 and its beta value stands at 1.23 points.
If we look at the previous 6 month’s performance of the stock, it remained pessimistic with the fall of -16.52%. In its last one month’s trade it declined -6.01%. ARIA has total market capitalization of $3.28 billion with a total of 166.66 million outstanding shares.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.